Naslov
Sicca symptoms and sialoadenitis as immune-related adverse events of nivolumab treatment in renal malignancy

Autori
Glavina, Ana ; Tadin, Antonija

Izvornik
MOJ Clinical & Medical Case Reports (2381-179X) 13 (2023), 1; 21-23

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Immune checkpoint inhibitors ; Nivolumab ; Sicca syndrome ; Sialadenitis
(immune checkpoint inhibitors ; nivolumab ; sicca syndrome ; sialadenitis)

Sažetak
Immune checkpoint inhibitors (ICIs) are a promising new type of immunotherapy for solid tumors and various hematologic neoplasms. Nivolumab is one of the ICIs and its target is programmed cell death 1 (PD-1). These therapies may lead to the development of immunerelated adverse events (irAEs). We present severe sicca symptoms in a 65-year-old patient in association with nivolumab. He was treated with nivolumab (monthly dose 480 mg) after left nephrectomy and secondary radiotherapy. Clinical oral examination revealed an extremely dry, mildly erythematous oral mucosa. The mucosa of the dorsum of the tongue was dry, atrophic, and “wrinkled.” Saliva was thick and sticky. The patient was prescribed local therapy: Pilocarpine drops 2%, six drops three times a day for six weeks. An oral antiseptic and an oral antifungal gel were prescribed to treat the oral candidiasis. Salivary gland function was monitored by serum alpha- amylase levels and results of unstimulated (UWS) and stimulated (SWS) whole saliva. The subjective symptom of dry mouth should not go unrecognized in patients treated with nivolumab, as timely therapeutic intervention is critical to preserve salivary function.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Dentalna medicina

POVEZANOST RADA